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Abstract
Protein export is essential in all bacteria and many bacterial pathogens depend on specialized
protein export systems for virulence. In Mycobacterium tuberculosis, the etiological agent of the
disease tuberculosis, the conserved general secretion (Sec) and twin-arginine translocation (Tat)
pathways perform the bulk of protein export and are both essential. M. tuberculosis also has
specialized export pathways that transport specific subsets of proteins. One such pathway is the
accessory SecA2 system, which is important for M. tuberculosis virulence. There are also
specialized ESX export systems that function in virulence (ESX-1) or essential physiologic
processes (ESX-3). The increasing prevalence of drug-resistant M. tuberculosis strains makes the
development of novel drugs for tuberculosis an urgent priority. In this article, we discuss our
current understanding of the protein export systems of M. tuberculosis and consider the potential
of these pathways to be novel targets for tuberculosis drugs.
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Mycobacterium tuberculosis, the causative agent of tuberculosis, is a serious global health
problem accounting for nearly two million deaths per year [1]. With the increasing
prevalence of multidrug resistant and extensively drug resistant M. tuberculosis there is an
urgent need to develop new antimycobacterial drugs. M. tuberculosis is spread through
aerosols and inhaled bacilli are engulfed by alveolar macrophages within the lungs. Instead
of being killed, M. tuberculosis survives within the phagosome compartment of the
macrophage, blocks phagosome maturation and replicates intracellularly [2]. The ability of
M. tuberculosis to survive and replicate within macrophages is essential for M. tuberculosis
pathogenesis. Another significant feature of M. tuberculosis is that it can persist long-term in
host granulomas and later reactivate to cause disease.
Mycobacterium tuberculosis poses unique challenges to drug development. One challenge is
for drugs to reach intracellular M. tuberculosis bacilli, which can be within granulomas. An
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additional challenge is presented by the unique structure of the mycobacterial cell envelope
(Figure 1) [3]. Mycobacteria have an atypical cell envelope characterized by a cell wall core
comprised of peptidoglycan that is covalently linked to arabinogalactan, which is in turn
attached to long chain mycolic acids. The mycolic acids, along with intercalating free lipids,
form a mycobacterial outer membrane, which was recently visualized for the first time by
cryoelectron microscopy [4,5]. Additionally, the mycobacterial outer membrane is
surrounded by a thick capsule composed of glycans, glycolipids and proteins [6]. The
complex cell envelope of mycobacteria represents a significant barrier to drug delivery.
All bacteria, including mycobacteria, possess protein export systems to transport proteins
synthesized in the cytoplasm beyond the cytoplasmic membrane. Exported proteins may
remain in the cell envelope or be further secreted beyond the bacterial cell wall. Many
exported proteins have essential functions that require an extracytoplasmic location.
Consequently, the protein export pathways themselves are commonly essential physiologic
processes. In addition to essential protein export pathways, bacterial pathogens commonly
have specialized protein export systems that are important for pathogenesis. Such pathways
are important to virulence because of their role in exporting effectors that interact with the
host.
Mycobacteria possess a functional general secretion (Sec) pathway and a twin-arginine
translocation (Tat) pathway for protein export. These conserved protein export pathways are
essential in M. tuberculosis. Mycobacteria also have specialized protein export systems,
dedicated to exporting subsets of proteins. The accessory SecA2 export system is
characterized by an additional copy of the SecA cytoplasmic ATPase and SecA2 is required
for M. tuberculosis virulence. Another set of specialized protein export systems in M.
tuberculosis are the five ESX pathways. The M. tuberculosis ESX pathways are named
ESX-1 to ESX-5. ESX-1 is important for virulence and ESX-3 is involved in iron
acquisition, an essential function for in vitro and in vivo growth.
In this article, we first summarize our understanding of Sec and Tat protein export from
studies in other bacteria, then review what is currently known about these conserved systems
in mycobacteria. We next discuss research on the specialized SecA2 and ESX export
systems in mycobacteria. Because all of the known export systems of M. tuberculosis are
either essential or important to virulence, we propose they be considered as new drug
targets. We end the article with discussion of recent progress in targeting protein export in
other bacteria and speculation on how these strategies could be extended to M. tuberculosis
in order to develop novel anti-mycobacterial therapies.
The general Sec secretion pathway
Over 20% of bacterial proteins have functions outside the cytoplasm and are exported to
their proper locations by protein export systems [7]. Although best studied in Escherichia
coli, all bacteria have a general (Sec) pathway, which performs the bulk of protein export
(for extensive reviews of Sec export, see references [8,9]). Sec export is an essential cellular
process, which makes the pathway a potential drug target.
Sec export is a post-translational process dedicated to exporting unfolded proteins. Central
to the Sec pathway is a heterotrimeric protein complex composed of the SecY, SecE and
SecG proteins [10]. The SecYEG complex forms a channel in the cytoplasmic membrane
through which proteins synthesized in the cytoplasm are transported to the extracytoplasmic
environment. Peripherally associated with the SecYEG channel is the cytoplasmic ATPase,
SecA, which together with SecYEG comprises the translocase. SecA targets proteins to the
SecYEG channel and drives these proteins through the channel with repeated rounds of
ATP-binding and hydrolysis [11]. While SecY, SecE and SecA are essential for protein
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export, SecG is expendable but increases the efficiency of export. Other auxiliary Sec
proteins that contribute to the efficiency of protein export, but are not essential for this
process, are SecD, SecF and YajC.
Proteins destined for Sec export are distinguished from the large pool of cytoplasmic
proteins by the presence of an N-terminal signal peptide and are called preproteins. Among
the proteins exported by the Sec system are lipoproteins, which contain a lipobox motif in
the C-terminal region of the signal peptide. The lipobox includes an invariant cysteine that is
the site of lipid modification [12]. During or shortly after translocation through the SecYEG
channel, the signal peptide is removed. This cleavage event takes place on the periplasmic
side of the membrane by one of two possible peptidases: the Type I signal peptidase (LepB)
or the lipoprotein Type II signal peptidase (LspA) [13]. After signal peptide cleavage, the
protein folds into a mature conformation.
The Sec pathway also participates in inserting integral membrane proteins into the
cytoplasmic membrane [14]. Integral membrane proteins are translocated cotranslationally
with the help of the signal recognition particle (SRP) and the membrane-bound SRP
receptor, FtsY. FtsY transfers nascent preproteins from SRP to the Sec translocase for
export. A lateral gate within the SecYEG channel allows the transmembrane domains to
embed in the membrane with assistance from the YidC protein [15].
The Sec pathway in mycobacteria
Mycobacteria have homologs of all the Sec export factors reviewed above (Figure 2A).
However, detailed studies have focused on only a few components of the mycobacterial Sec
pathway. The M. tuberculosis LspA removes signal peptides from lipoproteins [16]. An lspA
mutant of M. tuberculosis is attenuated in both macrophages and mice, illustrating the
importance of functional lipoproteins to M. tuberculosis virulence [16,17]. The other
components of the mycobacterial Sec pathway to receive attention are the SecA proteins.
Mycobacteria are unusual in having two homologs of SecA: SecA1 and SecA2. SecA1 is the
‘housekeeping’ SecA protein of mycobacteria, responsible for exporting the majority of
proteins. SecA2 is an accessory SecA, which is discussed in detail below. As is the case for
housekeeping SecA proteins of other bacteria, SecA1 of mycobacteria is essential. The
secA1 gene cannot be deleted from M. tuberculosis or the nonpathogenic Mycobacterium
smegmatis unless an exogenous copy of secA1 is provided [18–20]. The contribution of
SecA1 to protein export in mycobacteria can be examined by conditional silencing of secA1
in M. smegmatis [19]. Under the control of a tetracycline repressor, SecA1 depletion leads to
growth inhibition and decreased Sec export as evidenced by reduced export of the cell wall
porin, MspA [19,21].
Accessory SecA2 systems
Mycobacteria and some Gram-positive bacteria are unusual in having a second SecA in
addition to the canonical SecA1 [18,22]. This accessory SecA, called SecA2, is nonessential
in most bacteria with the exception of Corynebacterium glutamicum [23]. SecA2 systems
can be found in both pathogenic and nonpathogenic bacteria where they export specific
subsets of proteins (for an extensive review of accessory SecA2 systems, see [22]). In many
cases, SecA2 systems contribute to the virulence of bacterial pathogens [24–28].
Accessory SecA2 systems can be divided into two groups: those that include an accessory
SecY2 and those that do not. The emerging theme is that the SecA2/SecY2 systems export
large glycosylated proteins that are encoded near the secA2 and secY2 genes [24–26,28].
These exported proteins possess cleavable N-terminal signal peptides and are glycosylated
prior to export. Experiments in Streptococcus gordonii and Streptococcus parasanguinis
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with their respective SecA2/SecY2-exported proteins show that glycosylation of the mature
domains of these proteins prevents export via the canonical SecA1/YEG translocase [29,30].
Thus, it seems the SecA2/SecY2 systems are uniquely capable of accommodating export of
post-translationally modified proteins. In addition to the mature domain, features of the
signal peptide can be important for specifying SecA2/SecY2 substrates [31].
Mycobacterium tuberculosis and Listeria monocytogenes do not contain SecY2 proteins and
are examples of bacteria with SecA2-only systems. The exported proteins of SecA2-only
systems include examples of proteins with and without N-terminal signal peptides [27,32–
35]. The SecA2-only system of mycobacteria is discussed below.
The accessory SecA2 system of mycobacteria
While SecA1 of mycobacteria is essential and the corresponding gene cannot be deleted, the
gene encoding SecA2 can be deleted and secA2 mutants exist in M. smegmatis, M. bovis
Bacille Calmette-Guérin (BCG) and M. tuberculosis [18,32,36]. Importantly, a secA2 mutant
of M. tuberculosis is attenuated for growth in macrophages and in a mouse model of
tuberculosis infection [32,37]. These attenuated phenotypes show that the SecA2 export
pathway is important for M. tuberculosis virulence. The SecA2 proteins of M. smegmatis
and M. tuberculosis can each function in the opposite species, as shown by interspecies
complementation experiments [21]. Because of this functional conservation between SecA2
systems, the nonpathogenic M. smegmatis is often used to study the mechanisms of SecA2
export in mycobacteria.
As is true for SecA1 and the canonical E. coli SecA, SecA2 is an ATPase and ATP-binding
is necessary for SecA2 function in M. smegmatis and M. tuberculosis [21,38]. However,
there are also differences between the two SecA proteins. Importantly, SecA1 and SecA2 are
not functionally redundant. SecA2 overexpression cannot replace the requirement for SecA1
in mycobacteria and SecA1 overexpression cannot complement secA2 mutant phenotypes
[18]. Another difference between the two SecAs is revealed by subcellular fractionation
experiments. SecA1 is evenly distributed between the cytosolic and membrane fractions, as
is the case for the canonical SecA of E. coli [21]. The subcellular distribution of SecA2 is
notably different, with SecA2 being primarily cytosolic. This observation holds true for both
M. smegmatis and M. tuberculosis and it supports the existence of distinct functions for each
SecA protein [21]. Interestingly, an amino acid substitution in the ATP-binding site of
SecA2 (K129R) results in a dominant negative SecA2 that is defective in protein export and
localizes to the membrane instead of the cytosol [21]. The altered location of SecA2
(K129R) is consistent with a normally transient interaction between SecA2 and a
membrane-embedded translocase that is disrupted when SecA2 cannot hydrolyze ATP.
Two substrates exported by SecA2 in M. smegmatis are the cell wall lipoproteins
Msmeg1704 and Msmeg1712. These proteins were identified by comparing cell wall
proteins from wild-type M. smegmatis and the secA2 mutant using 2D-PAGE analysis [34].
Both of these SecA2 substrates are putative sugar-binding proteins of predicted ATP-
binding cassette (ABC) transporters and both proteins contain N-terminal Sec signal
peptides with lipobox motifs. In the absence of SecA2, these two lipoproteins are not
exported but other M. smegmatis lipoproteins are exported normally [34]. M. tuberculosis
does not have homologs of Msmeg1704 or Msmeg1712, but does contain other predicted
sugar-binding lipoproteins, which could be important for virulence. It is unknown if SecA2
is required for export of these M. tuberculosis proteins.
Because mycobacteria do not have an accessory SecY2 or obvious alternative translocase, a
fundamental question about the mycobacterial SecA2 system is whether it works with the
canonical SecA1/SecYEG translocase or an unidentified channel to export its select subset
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of proteins. To test these possibilities, the effect of SecA1 depletion on Msmeg1712 export
was tested. When SecA1 is depleted, export of Msmeg1712 is significantly reduced and this
export defect is equivalent to that seen in a secA2 mutant [21]. This result reveals a role for
both SecA1 and SecA2 in exporting Msmeg1712 and it suggests that SecA2 works in
concert with the canonical Sec machinery.
The aforementioned studies support a developing model for SecA2 export in mycobacteria
(Figure 2B). SecA1 shuttles evenly between the cytosol and the SecYEG membrane channel
to continually deliver and translocate exported proteins. In contrast, SecA2 is primarily
cytoplasmic where it may function to recognize or deliver proteins that are normally
overlooked by SecA1 to the canonical SecA1/SecYEG translocase for export. Another
possibility is that SecA2 is required to energize a specific subset of proteins across the
canonical translocase. Alternatively, SecA1 and SecA2 may work together to promote
export of proteins through a novel translocase in the membrane other than SecYEG.
In a comparative 2D-PAGE analysis of wild-type M. tuberculosis and the secA2 mutant,
SecA2-dependent proteins secreted into the culture media were identified [32]. As observed
in the cell wall analysis in M. smegmatis, only a small number of proteins were identified as
secreted less into culture media by the secA2 mutant. In this case, all three proteins
identified lack recognizable signal peptides. One of these SecA2-dependent M. tuberculosis
exported proteins is the Fe-superoxide dismutase, SodA [32]. Experiments confirm that
secretion of SodA protein and superoxide dismutase activity are both reduced in the secA2
mutant [32,39]. Interestingly, one of the SecA2-secreted proteins of L. monocytogenes is a
Mn-superoxide dismutase, MnSOD, which also lacks a signal peptide [35]. This suggests a
common mechanism of SecA2 export between pathogenic M. tuberculosis and L.
monocytogenes.
It remains to be reconciled how SecA2 is involved in exporting proteins that lack signal
peptides in M. tuberculosis and proteins with signal peptides in M. smegmatis. One
possibility is that the proteins exported by SecA2 are not recognized on the basis of the
signal peptide and both signal peptide-containing and signal peptide-lacking proteins can be
recognized and exported by SecA2. An alternative is that the role of SecA2 in the secretion
of proteins lacking signal peptides is indirect. SecA2 may export a currently unknown
protein containing a signal peptide. This unknown protein could itself be part of a
specialized secretion apparatus through which proteins such as SodA are secreted.
As previously mentioned, analysis of the secA2 mutant of M. tuberculosis shows that the
SecA2 system is important to virulence. Because SodA is an antioxidant, the identification
of SodA as a SecA2-dependent protein suggests that the role of the SecA2 system might be
to protect M. tuberculosis against reactive oxygen intermediates produced by macrophages.
However, the M. tuberculosis secA2 mutant is attenuated for growth in macrophages even if
they are derived from phox−/− mice, which are unable to elicit an oxidative burst [37]. While
these results with phox−/− macrophages do not rule out a role for the SecA2 system in
resisting oxidative stress, it does reveal another role for SecA2 export beyond detoxification
of reactive oxygen intermediates. This result also implies that proteins other than SodA are
exported by the SecA2 system of M. tuberculosis. Another possible role for SecA2 in M.
tuberculosis is inhibiting the innate immune response. This possibility is supported by the
observation that macrophages infected with the M. tuberculosis secA2 mutant produce
higher levels of proinflammatory cytokines and exhibit more apoptosis than wild-type
infected macrophages [37,39]. The secA2 mutant of M. tuberculosis also elicits better
protective immunity to M. tuberculosis challenge in mice and guinea pigs than vaccination
with the M. bovis BCG vaccine [39].
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In the future, it will be important to identify all the M. tuberculosis proteins exported by the
SecA2 system. This information will help us better understand the process of SecA2 export
and the role of SecA2 in virulence and protective immunity.
The Tat export pathway
Like the general Sec pathway, the Tat pathway exports proteins with N-terminal signal
peptides beyond the cytoplasmic membrane (for an extensive review of Tat export, see [8]).
The Tat pathway is found in many Gram-positive and Gram-negative bacteria but, unlike the
Sec pathway, is not present in all bacteria [40]. Also, the Tat system differs from the Sec
system because it only exports proteins that are prefolded in the cytoplasm.
Preproteins destined for Tat export have N-terminal signal peptides similar to Sec signal
peptides [41]. However, a distinguishing feature of Tat signal peptides is the presence of a
pair of arginine residues (RR) that are contained within the Tat motif, RRXΦΦ, where Φ is a
hydrophobic residue. The RR pair is nearly invariant and replacement of both arginines with
lysine residues abolishes Tat-dependent export [42].
The Tat export machinery consists of two core components: the TatA and TatC integral
membrane proteins. A third protein, TatB, is similar to TatA in amino acid sequence but not
all bacteria have a TatB ortholog. The mechanisms of Tat export are less understood than
those of Sec export, but there is a growing understanding of the process (Figure 2C) [41].
The current model is that a Tat signal peptide targets a folded preprotein to the TatBC
complex in the cytoplasmic membrane. With energy supplied by proton motive force, TatA
is then recruited to the TatBC complex and forms a homo-oligomeric translocase channel.
There is evidence that the size of the TatA pore can vary, which may explain how the pore
can handle folded proteins of different shapes and sizes. The preprotein is then translocated
across the cytoplasmic membrane through the TatA channel and the signal peptide is
removed by a Type I signal peptidase [43]. Type II signal peptidases may also act on Tat
precursors since some Tat signal peptides contain lipobox motifs. For example, in Haloferax
volcanii a lipoprotein is exported by the Tat pathway [44]. There is also a category of Tat
substrates that become integrally embedded in the membrane [45].
A folded conformation prior to export is not only a characteristic of Tat substrates, but is
actually a requirement for Tat export. Proteins are only exported by the Tat system when
conditions are favorable for cytoplasmic folding [46]. Therefore, in addition to the Tat signal
peptide there are features of the mature domain of Tat substrates that promote folding and
thereby dictate Tat export [47].
The Tat pathway is present and linked to virulence in a number of bacterial pathogens
(reviewed in [48]). In Pseudomonas aeruginosa, the Tat pathway exports multiple virulence
factors and a mutant defective in Tat export is attenuated in the rat model of infection [49].
Two of the Tat-dependent virulence factors in P. aeruginosa are secreted phospholipase C
enzymes [49]. In Legionella pneumophila, Tat export is required for replication in the
amoeba host as well as in macrophages [50,51]. Furthermore, the L. pneumophila
phospholipase C enzyme also requires the Tat pathway for export [51].
The mycobacterial Tat pathway
The Tat pathway is functional in both M. tuberculosis and M. smegmatis. Both species
contain genes encoding TatA, TatB and TatC. Tat export is essential for growth of M.
tuberculosis, at least under standard laboratory conditions, as shown by the inability to
delete tatA, tatB, or tatC unless exogenous copies of the tat genes are provided [52].
However, deletion mutants of tatA, tatB and tatC can be made in M. smegmatis. These
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mutants have growth defects in vitro; nonetheless, M. smegmatis tat mutants can be utilized
to study Tat export in mycobacteria [53,54].
Another phenotype of M. smegmatis tat mutants is increased sensitivity to β-lactam
antibiotics [53,54]. Because β-lactamases need to be exported to the cell wall in order to
degrade β-lactams, the hypersensitivity of these tat mutants can be attributed to reduced
export of the β-lactamase, BlaS. M. smegmatis BlaS has a predicted Tat signal peptide and
BlaS is not exported by a tat mutant [53,54]. By expressing the M. tuberculosis β-lactamase
(BlaC) in wild-type M. smegmatis and tat mutants, the Tat dependence of BlaC is also
established [53]. Furthermore, when the RR dipeptide of the BlaC signal peptide is changed
to KK, BlaC export in M. smegmatis is abolished, indicating that the twin-arginine motif is
required for Tat export in mycobacteria, as expected [53].
In silico analysis of the M. tuberculosis genome using several Tat prediction programs
predicts a total of 108 proteins with Tat signal peptides [55,56]. Some of these predicted Tat
substrates have demonstrated or suggested roles in M. tuberculosis pathogenesis or essential
physiologic processes. However, relying exclusively on Tat prediction programs to identify
Tat substrates is risky. The current Tat prediction programs are built on Tat consensus
sequences defined in bacteria other than mycobacteria. There is also little overlap in the
predictions of the currently available Tat prediction programs [56]. Furthermore, there is an
increasing list of unusual Tat exported proteins that lack a cleavable signal peptide with a
twin arginine motif and are missed by the current programs [57].
To overcome some of the bias of Tat prediction programs, a genetic reporter approach can
be used to identify Tat-exported proteins of M. tuberculosis [56]. This approach utilizes a
BlaC reporter lacking its endogenous Tat signal peptide and a β-lactam-sensitive blaC or
blaS mutant mycobacteria background. When the signal peptide from a Tat substrate is
fused to BlaC, the resulting fusion protein can be exported and confer β-lactam resistance,
reporting on Tat export. Importantly, the BlaC reporter only works when exported by the Tat
pathway and not by the Sec pathway [53]. Using the BlaC reporter, 17 M. tuberculosis
proteins are shown to have functional Tat signal peptides [55,56]. The list of proteins with
proven Tat signal peptides includes two phospholipase C proteins, PlcA and PlcB.
Phospholipase C is necessary for the full virulence of M. tuberculosis in mice, providing
strong evidence that the Tat pathway contributes to M. tuberculosis pathogenesis [58].
Another protein identified as having a functional Tat signal peptide is Rv2525c, which is
suggested to have a role in infection by the demonstration of increased virulence of a M.
tuberculosis rv2525c mutant in macrophages and mice [52,56].
ESX export pathways in mycobacteria
Mycobacterium tuberculosis also has five specialized ESX export systems (ESX-1 to
ESX-5). The ESX systems are named for the first known secreted substrate of any ESX
pathway, the 6kDa early secreted antigenic target (ESAT-6) of M. tuberculosis. The
hallmark of the ESX systems is that they secrete small proteins with homology to ESAT-6.
These ESAT-6-like proteins (Esx) lack Sec or Tat signal peptides and rely on ESX systems
for secretion. Although the ESX systems were first discovered in M. tuberculosis they also
exist in a small subset of Gram-positive bacteria. More recently, ESX systems have been
referred to as Type VII secretion systems (for an extensive review of ESX systems, see
[59]).
Each of the five ESX loci has a pair of genes encoding secreted Esx proteins as well as a
suite of genes encoding the secretion machinery. The first ESX system identified was ESX-1
and it is the best described of the systems. At the center of the ESX-1 locus (spanning genes
rv3864–rv3883c) are the esxA and esxB genes, which encode ESAT-6 (EsxA) and culture
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filtrate protein 10 kDa (CFP-10; EsxB) (Figure 3B) [59]. CFP-10 is an ESAT-6-like protein
that is co-secreted with ESAT-6. Other genes in ESX-1 encode predicted membrane proteins
and ATPases, many of which are required for secretion of ESAT-6 and CFP-10 [60–64]. An
additional locus involved in ESX-1 secretion is located at a distal site (rv3616c–3614c)
[65,66]. Interestingly, ESAT-6 and CFP-10 are not produced by the attenuated M. bovis
BCG vaccine strain. This is because the genomic region of difference 1 (RD1), which is
deleted in BCG but present in the genomes of M. tuberculosis and of M. bovis, includes part
of the ESX-1 locus [67].
ESX-1
The ESX-1 pathway is required for full virulence in several pathogenic mycobacteria [59].
Mutations throughout the ESX-1 locus in M. tuberculosis, M. bovis and M. marinum lead to
attenuated phenotypes in macrophages and mice [60–65,68–70]. M. marinum is a fish
pathogen that has a ESX-1 pathway homologous to M. tuberculosis. There are many
reported effects of the ESX-1 system on the host; however, additional research is required to
determine which of these effects account for the ESX-1 function in virulence. During
macrophage infection with M. tuberculosis or M. marinum, ESX-1 contributes to the process
of blocking phagosome maturation [71,72]. ESX-1 also limits the production of several
proinflammatory cytokines that are important for controlling M. tuberculosis [64]. The
ability to disrupt membranes is a property of ESAT-6; therefore, another role for the ESX-1
system may be to lyse host cell membranes [62,73–75]. A function in membrane disruption
could explain the data showing that ESX-1 promotes host cell necrosis, bacterial spread to
other cells and even phagosomal escape of M. tuberculosis and M. marinum in infected host
cells [61,62,70,75,76]. Finally, experiments with M. marinum in a zebrafish model show
ESX-1 promotes recruitment of uninfected macrophages to nascent granulomas, which
appears to aid in proliferation and spread of the bacteria [77].
ESX-3
The ESX-3 pathway is essential in M. tuberculosis as shown by analysis of an esx-3
conditional mutant [78,79]. The growth defect of esx-3 mutants is attributed to defects in
siderophore-dependent iron acquisition. The growth phenotype of esx-3 mutants can be
transcomplemented by co-culture with a wild-type strain, suggesting one or more ESX-3
secreted factors are important for ESX-3 mediated iron acquisition.
ESX-2 & -4
The ESX-2 and ESX-4 systems have not been directly studied in mycobacteria; however,
whole genome mutagenesis studies do not predict a requirement for ESX-2 or ESX-4 for in
vitro growth or virulence [80,81].
ESX-5
There are no reported studies of ESX-5 in M. tuberculosis and the locus is not predicted to
be important for in vitro growth or virulence [80,81]. However, in M. marinum, ESX-5 is
required for export of many PE/PPE proteins [82,83]. PE/PPE proteins are a highly abundant
but poorly understood family of proteins restricted to mycobacteria. PE and PPE proteins
contain N-terminal domains rich in Pro–Glu (PE), or Pro–Pro–Glu (PPE) repeats connected
to a variable C-terminal domain giving them their name. The best characterized of these
ESX-5-secreted PPE proteins is PPE41, which lacks a Sec or Tat signal peptide [82].
ESX secreted proteins & machinery
All five ESX loci in mycobacteria are characterized by a pair of esx genes, encoding
homologs of ESAT-6 and CFP-10 and genes encoding the secretion machinery [59,84]. Our
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understanding of how ESX systems work comes almost exclusively from research on ESX-1
and is described below.
ESX secreted proteins—The best-studied ESX secreted proteins, ESAT-6 and CFP-10,
are secreted as a heterodimer [85]. ESAT-6/CFP-10 complex formation is required for
stabilizing each protein. The complex is also important for secretion because CFP-10, but
not ESAT-6, has a C-terminal signal peptide that targets the protein complex to the export
machinery [86]. Other proteins secreted by the ESX-1 system are EspR, EspA, EspB and
EspC, [65,69,87,88]. These proteins are not homologous to ESAT-6 and they are larger than
ESAT-6. However, like ESAT-6 and CFP-10, these Esp secreted proteins lack N-terminal
Sec or Tat signal peptides.
EspR is a particularly interesting protein secreted by the ESX-1 system. EspR is a
transcriptional activator that regulates ESX-1 secretion. More specifically, EspR regulates
expression of the espACD genes, which are required for ESAT-6/CFP-10 export. When the
ESX-1 pathway is active, EspR is secreted, resulting in reduced expression of espACD.
Conversely, when the ESX-1 pathway is inactive, the cytosolic levels of EspR increase,
which results in increased transcription of espACD [87].
ESAT-6 and CFP-10 are secreted as a complex in a co-dependent fashion. Co-dependent
secretion is also observed for other ESX-1 secreted proteins [65,88]. For example, EspA
depends on ESAT-6/CFP-10 for its secretion and, conversely, ESAT-6/CFP-10 depends on
EspA for secretion [65]. These co-dependent relationships suggest an interaction prior to
secretion and it raises the possibility that the secreted proteins known so far are actually part
of the ESX-1 machinery as opposed to being virulence factors that act on the host. Thus, it is
possible that the ESX-1 secreted proteins with direct roles in virulence remain to be
identified.
ESX machinery—Each ESX locus contains genes encoding conserved secretion
machinery components termed EccABCDE and MycP. All of these core components are
required for ESAT-6/CFP-10 secretion [60,61,63–65,70].
ESX-associated AAA ATPases (EccA1 & EccCb1)—Both EccA1 and EccCb1 are
predicted cytoplasmic AAA ATPases, suggesting that these proteins supply energy for the
secretion process. For EccA1, in vitro ATPase activity has been demonstrated [89]. Each of
these ATPases is involved in targeting proteins for ESX-1 secretion. EccCb1 binds a seven
amino acid C-terminal signal peptide of CFP-10, which is required for secretion of the
ESAT-6/CFP-10 complex [86]. Similarly, EccA1 binds a C-terminal region of EspC that is
required for secretion [88].
ESX membrane proteins (EccCa1, EccB1, EccD1, EccE1 & MycP1)—EccD1 has
10–11 predicted transmembrane domains with short periplasmic and cytoplasmic loops,
suggesting a possible role as a channel used for protein translocation across the cytoplasmic
membrane. EccCa1 is a predicted integral membrane protein that interacts with the ATPase
EccCb1, discussed above [64]. EccB1 and EccE1 are predicted transmembrane proteins with
domains in the periplasm [90]. EccE1 is shown to interact with EspD, a cytoplasmic protein
of unknown function that is required for ESAT-6/CFP-10 secretion [66].
MycP1 has a single predicted transmembrane domain at the C-terminus and the protein
localizes to the cytoplasmic membrane and cell wall of M. tuberculosis [91]. MycP1 is a
serine protease that cleaves EspB after export [63]. As with all the core components,
deletion of mycP1 eliminates ESX-1 secretion. Surprisingly, point mutations inactivating the
protease activity of MycP1 do not eliminate secretion but result in higher than normal levels
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of ESAT-6 secretion. Together, these results suggest two roles for MycP1 in ESX-1
secretion. First, MycP1 has an undefined role in ESX-1 secretion that is independent of its
protease activity. Second, the protease activity of MycP1 has a negative regulatory effect on
ESX-1 export. A smaller, possibly processed form of MycP1 is found in the culture
supernatant and in macrophages infected with M. tuberculosis; however, the significance of
this cleaved product is unknown [91].
Model of ESX-1 transport
While conserved core components are defined in the ESX systems, the specific roles of
these core proteins are still being clarified. Nevertheless, with the existing data it is possible
to start building a model describing ESX secretion (Figure 3). Substrates containing a C-
terminal signal peptide (i.e., CFP-10 or EspC) or secreted proteins bound to such proteins
(i.e., ESAT-6) are targeted to a cytoplasmic ATPase, such as EccA1 or EccCb1. In turn
these ATPases interact with membrane proteins that are likely to assemble into a
multiprotein translocation complex. EccD1 is the most attractive candidate for the
translocation channel and the energy to drive the export process may be supplied by ATP
hydrolysis. It is important to point out that this model only accounts for how exported
proteins traverse the cytoplasmic membrane. How ESX-1 secreted proteins cross the
mycobacterial outer membrane is an important question that remains to be addressed.
Protein export systems as targets for new drug development
The increasing prevalence of drug-resistant strains of M. tuberculosis makes the
development of novel drugs for tuberculosis an urgent priority. When exploring options for
new drug targets of M. tuberculosis, there are several criteria that should be considered [92].
First, the drug target must be essential to bacterial viability, virulence or the persistence of
M. tuberculosis in granulomas. We include virulence pathways as potential targets because
antivirulence therapies are a new and promising approach to developing antimicrobial agents
[93]. Second, targeting a novel pathway not inhibited by existing drugs may reduce the
chance of cross-resistance with current drug-resistant strains. Third, targets not conserved in
humans may reduce the likelihood of off-target effects. Fourth, the target should be
amenable to high-throughput assays to screen for inhibitors. Fifth, the target must be
accessible to inhibitors, which is particularly important for penetrating the unique and highly
impermeable cell envelope of M. tuberculosis. In general, targets that are positioned outside
the cytoplasmic membrane will be more accessible to drugs. Finally, a target with a known
function is advantageous for drug optimization. The concept of developing drugs that inhibit
bacterial protein export systems is not new and there are reports of inhibitors of both
conserved and specialized export systems (discussed below) [94,95]. Despite this, there are
no approved drugs that target protein export.
The protein export pathways of M. tuberculosis satisfy nearly all of the above criteria for
new drug targets. Many of the export pathways of M. tuberculosis are essential for in vitro
growth or are required for virulence. Protein export is not exploited by existing M.
tuberculosis drugs and many components of the mycobacterial protein export systems are
not conserved in humans. Finally, some components of M. tuberculosis protein export
systems are themselves secreted or have active domains positioned outside of the cytoplasm.
Below, we review efforts to target protein export systems in other bacteria. Because no such
efforts have been applied to M. tuberculosis yet, we end with speculation on how inhibitors
against components of the M. tuberculosis export systems could be identified.
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Identification of Sec export inhibitors
The Sec export system is highly conserved and essential in all bacteria, making this pathway
an attractive broad-spectrum drug target. One approach used to identify inhibitors of Sec
export is whole-cell screening using an E. coli strain carrying a secA–lacZ reporter fusion
[96]. This screening strategy relies on the fact that SecA expression increases when Sec
export is blocked. Inhibitors of Sec export are identified as inducers of secA–lacZ
expression. This screening method identified compounds that are bactericidal against
Staphylococcus aureus and reduce export of the toxic shock syndrome toxin-1. However,
these compounds also cause membrane damage in both S. aureus and eukaryotic cells,
eliminating the possibility of therapeutic use. Nevertheless, this type of whole-cell screen
may be useful in the future if it can be optimized to avoid selection of membrane-damaging
agents.
An alternate strategy to target the Sec pathway is to search for inhibitors of specific Sec
components: the SecYEG membrane channel, SecA ATPase or the signal peptidases. With
the exception of SecG, all of these proteins are essential for Sec export and would cause cell
death if targeted. The eukaryotic endoplasmic reticulum contains proteins homologous to
SecY (Sec61α) and SecE (Sec61γ) making these members of the translocase unattractive
targets. However, this does not eliminate the possibility of finding novel inhibitors that
indirectly target SecY or SecE. Some currently used antibiotics indirectly target SecY for
degradation by stalling protein translation and jamming the SecYEG translocase [97].
Unlike SecY and SecE, there is no eukaryotic homolog of SecA, making it a promising
target for inhibitors of Sec export. Inhibitors of in vitro SecA ATPase activity were
identified using the crystal structure of E. coli SecA and structure-based virtual screening of
compounds [98]. With optimization, two of these inhibitors became effective against SecA
in the micromolar range in a biochemical ATPase assay [99]. However, when tested on
whole cells these compounds only elicit growth inhibition of an E. coli strain with increased
membrane permeability, indicating that further optimization is needed in order to access
SecA in wild-type strains. In another approach, SecA inhibitors were identified by screening
a S. aureus strain expressing antisense RNA to secA. This antisense strain has increased
sensitivity to inhibitors of SecA, which makes them easier to identify [100]. One of these
compounds identified is pannomycin, which is structurally similar to a demonstrated SecA
inhibitor identified independently in another study [100,101]. While pannomycin has low
antibacterial activity against a panel of bacteria tested, there is potential in optimizing its
activity [99,100].
An alternative strategy to inhibit Sec export is to target the signal peptidases that cleave
signal peptides from preproteins. The active sites of signal peptidases are located on the
periplasmic side of the membrane, which bypasses the need to penetrate the membrane with
inhibitors [102]. Type I signal peptidases are essential in all bacteria tested, making them
good drug targets [103,104]. Furthermore, the catalytic domain of bacterial Type I signal
peptidases is highly conserved among Gram-positive and -negative bacteria, which could
lead to broad-spectrum inhibitors [13]. Even though eukaryotic cells have signal peptidases,
their catalytic domains differ from those of bacterial Type I signal peptidases making off-
target effects of inhibitors unlikely [13]. Penem compounds inhibit the E. coli Type I signal
peptidase by mimicking the peptide bond of natural substrates [105–107]. Some of these
compounds work with both E. coli and S. aureus in cell-based assays [107]. There is also a
class of lipopeptides called arylomycins, which act against Type I signal peptidases and are
bactericidal against Gram-positive, but not Gram-negative, bacteria [108,109]. The bacterial
Type II signal peptidase represents another possible drug target. There are no eukaryotic
homologs of Type II signal peptidases and the antibiotic globomycin inhibits these enzymes
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[110]. While antibacterial globomycin derivatives that work on Gram-negative and Gram-
positive bacteria exist, globomycin is not used therapeutically [111].
Identification of Type III secretion Inhibitors
Type III secretion systems (T3SSs) are specialized protein export systems used by Gram-
negative pathogens. T3SSs employ a needle-like multiprotein complex to directly inject
bacterial virulence factors into host cells. Many Gram-negative pathogens rely on T3SS
effectors to infect host cells or evade host responses [112]. There is recent success with cell-
based screening to identify inhibitors of T3SSs. While mycobacteria do not have T3SSs,
identification of T3SS inhibitors in Gram-negative pathogens highlights the potential of
developing similar screens to find inhibitors of specialized export systems in M.
tuberculosis.
In Yersinia pseudotuberculosis, the T3SS secretes Yop proteins, including YopE. YopE is
highly expressed when the T3SS is active and its expression is repressed by the LcrQ
regulator, which is itself secreted by the T3SS. When T3SS secretion is not active, LcrQ
accumulates in the cytosol and blocks YopE expression. Inhibitors of the T3SS were
identified by screening a library of compounds against a Y. pseudotuberculosis strain
containing a pyopE–luxAB reporter fusion. The most potent T3SS inhibitors identified in this
screen are acylated hydrazones of various salicylaldehydes [113,114]. These compounds
reduce Y. pseudotuberculosis and Chlamydia pneumoniae replication in HeLa cells, which
validates the concept of targeting specialized secretion systems for drug development
[114,115]. Using a screening strategy very similar to that described for Y.
pseudotuberculosis, inhibitors of the Pseudomonas aeruginosa T3SS were also identified.
The most promising of these T3SS inhibitors is a phenoxyacetamide that also works on the
T3SS in other Gram-negative pathogens [116].
Future perspective: identification of inhibitors of mycobacterial protein
export
Mycobacterial protein export systems satisfy many criteria of good drug targets but they
have yet to be exploited as such. Below we discuss the potential of targeting M. tuberculosis
protein export systems and speculate on experimental approaches that could be used to
identify inhibitors.
Targeting mycobacterial Sec export
As in other bacteria, the canonical Sec pathway of M. tuberculosis is essential and the
SecA1 ATPase a good target for inhibiting Sec export. The crystal structure of M.
tuberculosis SecA1 is very similar to the SecAs of E. coli and Bacillus subtilis, suggesting
similar mechanisms of action and highlighting the possibility of optimizing SecA inhibitors
discussed above for use in mycobacteria [117,118]. Because the functional domains of M.
tuberculosis SecA1 are conserved in SecA2 and both SecAs are demonstrated ATPases, it
may even be possible to develop inhibitors that target both SecA proteins [21]. Targeting
both SecA proteins simultaneously would inhibit both M. tuberculosis growth and virulence.
It is also possible to search for inhibitors of the M. tuberculosis Sec pathway directly with
cell-based screening, which will ensure the inhibitors penetrate the mycobacterial cell
envelope. One possible method for finding SecA inhibitors in mycobacteria is to employ a
whole-cell antisense-based screening method, as was done in S. aureus [100]. A second
approach is to generally screen for inhibitors of Sec export using a mycobacterial strain
engineered to export a reporter protein via the Sec pathway. One possible strategy is to
express the TEM-1 β-lactamase, which is an established reporter of Sec export in M.
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tuberculosis, in either a blaC mutant of M. tuberculosis or blaS mutant of M. smegmatis
[119]. Compounds could be screened for inhibition of secreted β-lactamase activity in
culture supernatants of the reporter strains, using the chromogenic β-lactam nitrocefin
[116,119,120]. Export of the TEM-1 β-lactamase reporter also protects the β-lactam
sensitive mycobacterial bla mutants from β-lactam antibiotics. Therefore, inhibitors could
also be screened for loss of β-lactam resistance in this system.
Mycobacterium tuberculosis signal peptidases are other components of the Sec export
machinery that could be targeted directly. The Type I signal peptidase of M. tuberculosis,
LepB, is predicted to be essential [80]. The progress in developing inhibitors of Type I
signal peptidase in other bacteria is encouraging and could be extended for use against M.
tuberculosis. The M. tuberculosis Type II signal peptidase, LspA, could also be targeted. An
lspA deletion mutant of M. tuberculosis is attenuated in mice, which suggests inhibitors of
Type II signal peptidases could have therapeutic value [16]. Globomycin is an available
Type II signal peptidase inhibitor. Interestingly, globomycin kills M. tuberculosis but the
bactericidal effect is independent of LspA and remains to be elucidated [121].
Targeting mycobacterial Tat export
There are many features of the Tat export pathway that make it an attractive drug target
[122]. Most importantly, Tat export is essential in M. tuberculosis [52]. Furthermore, Tat
inhibitors are unlikely to cause off-target effects on the host as no mammalian homologs of
Tat machinery exist. There are also extracytoplasmic domains of the membrane-embedded
Tat proteins to help drug accessibility. The endogenous M. tuberculosis β-lactamase (BlaC)
is a Tat substrate and can be used as a reporter for Tat-export [53]. In a similar strategy as
that proposed for finding inhibitors of Sec export in mycobacteria, inhibitors of Tat export
could be identified by screening a library of chemical compounds for reduction in BlaC
export.
Targeting mycobacterial ESX export
The specialized ESX export systems represent other potential targets for new anti-
tuberculosis drugs. Of the five M. tuberculosis ESX pathways, ESX-1 and ESX-3 are known
to be essential for virulence and growth of M. tuberculosis, respectively. An inhibitor that
targets a conserved core component of the ESX pathways has the potential to disrupt all
ESX systems simultaneously, which could reduce the potential for drug resistance to arise.
The ESX systems meet many of the desired criteria for new drug targets. There are no
known homologs to ESX systems in eukaryotic organisms. The ESX export pathways have
a relatively high number of core components with predicted periplasmic domains (EccB,
EccD, EccE and MycP). There are also secreted proteins of the ESX system that may
function in the ESX secretion process (EspA and ESAT-6/CFP-10) that could be accessible
to inhibition.
Unlike the Sec and Tat pathways, ESX systems do not have established reporters to test
ESX activity. However, EspR has potential to be exploited as a reporter of ESX-1 activity.
Similar to the transcriptional regulator LcrQ of Y. pseudotuberculosis T3SS, the EspR
transcriptional activator is itself secreted by ESX-1. When ESX-1 is not active, EspR
accumulates in the cytosol and induces espACD expression [87]. Using mycobacteria
carrying a transcriptional fusion of the espACD promoter to luciferase, high-throughput
screens could be conducted for compounds that inhibit ESX-1 secretion. An inhibitor of the
ESX-1 system would lead to increased cytosolic EspR and induced expression of the
reporter construct.
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Protein export is essential for M. tuberculosis growth and virulence. It is our belief that the
protein export systems of M. tuberculosis represent novel pathways that could be targeted
for drug development. While the basic aspects of the protein export systems of M.
tuberculosis are known, there remains much to be learned. In particular, we do not fully
understand how the accessory SecA2 and specialized ESX systems operate or contribute to
pathogenesis. A wealth of potential drug targets may exist within these and other protein
export pathways of M. tuberculosis.
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Figure 1. Barriers to effective drug delivery for Mycobacterium tuberculosis infection
M. tuberculosis is an intracellular pathogen that can reside long-term within macrophages in
granulomas. Additionally, M. tuberculosis has an unusual and complex cell wall that is a
physical barrier for drug delivery. The outermost layer of the cell wall is composed of a
glycan- and glycolipid-based capsule, followed by the mycobacterial outer membrane. The
mycobacterial outer membrane is composed of free lipids intercalated with mycolic acids
that are covalently linked to the arabinogalactan component of the cell wall. The
arabinogalactan is, in turn, covalently linked to peptidoglycan. The cytoplasmic membrane
is the final permeability barrier before the cytosol.
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Figure 2. The Sec, SecA2 and Tat protein export systems of mycobacteria
(A) The conserved Sec pathway exports unfolded preproteins that are synthesized with N-
terminal signal peptides (hatched marks). The SecA ATPase recognizes and drives
preproteins through the SecYEG membrane channel using repeated rounds of ATP-binding
and hydrolysis. The SecD, SecF and YajC proteins increase efficiency of Sec protein export.
During or shortly after translocation, the signal peptide is removed by a membrane-bound
SP. The exported protein folds into a mature conformation. (B) The accessory SecA2 system
of mycobacteria is characterized by a functionally distinct ATPase called SecA2, which is
required for the export of a subset of proteins. Current data suggests that SecA2 uses the
canonical SecA1/SecYEG translocase for exporting proteins, but the possibility of a
requirement for a distinct channel within the membrane has not yet been eliminated. Some
SecA2-dependent exported proteins have signal peptides and some do not. The role of
SecA2 in the export of proteins lacking signal peptides is unresolved. (C) The conserved Tat
pathway exports folded preproteins containing N-terminal signal peptides with a twin-
arginine (RR) motif. Tat preproteins are recognized by the TatBC complex in the membrane
and then translocated across a homo-oligomeric TatA channel. As with Sec export, the
signal peptide is removed by a membrane-bound SP.
RR: Arginine residues; Sec: Secretion; SP: Signal peptidase; tat: Twin arginine
translocation.
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Figure 3. The ESX-1 system of Mycobacterium tuberculosis
(A) The core components of the ESX-1 pathway are EccA1, EccB1, EccCa1, EccCb1,
EccD1, EccE1 and MycP1. In the developing model of ESX export, C-terminal signal
peptides of ESX-1 substrates (EspC and CFP-10) are recognized by cytoplasmic AAA
ATPases (EccA1 and EccCb1). Through interactions with membrane components of the
ESX-1 system, the ATPases are proposed to deliver these proteins to the translocation
channel. EccD1 is the putative membrane channel through which the proteins are
translocated. (B) The genomic ESX-1 locus of M. tuberculosis is shown along with the
distally located espACD and espR genes. The RD1 deleted in BCG is indicated. (C) There is
a recently introduced systematic nomenclature for genes of the ESX-1 locus [84]. The new
gene names and previously used nomenclature, derived from the M. tuberculosis genome
annotation, are shown.
BCG: Bacille Calmette-Guérin; CFP: Culture filtrate protein; ESAT: Early secreted
antigenic target; RD1: Region of difference 1.
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